18:17:29 EDT Mon 02 Aug 2021
Enter Symbol
or Name
USA
CA



Login ID:
Password:
Save
Hemostemix Inc (2)
Symbol HEM
Shares Issued 56,276,894
Close 2021-05-28 C$ 0.26
Recent Sedar Documents

Hemostemix to hold annual meeting virtually

2021-05-31 11:09 ET - News Release

Mr. Thomas Smeenk reports

HEMOSTEMIX ANNOUNCES THAT, DUE TO THE COVID-19 PANDEMIC, THE ANNUAL AND SPECIAL MEETING WILL ONLY BE HELD VIA ZOOM AND SHAREHOLDERS ARE REQUESTED TO FOLLOW THE MEETING INSTRUCTIONS MAILED TO THE SHAREHOLDERS OF RECORD

Hemostemix Inc. has reminded shareholders that, due to COVID-19, its annual and special meeting will be held by Zoom only.

Shareholders are invited to the scheduled Zoom meeting, per the information circular mailed to all shareholders of record.

Topic: The annual and special meeting of the shareholders of Hemostemix

Time: May 31, 2021, 11 a.m. MST (Calgary)

Meeting ID: 874 2715 8805

Pass code: 381727

One tap mobile

1-929-205-6099, 87427158805 followed by the number sign, *381727 by the number sign, United States (New York)

12532158782, meeting ID 874 2715 8805 followed by the number sign, *381727 followed by the number sign, United States (Tacoma)

Dial by your location

1-929-205-6099, United States (New York)

1-253-215-8782, United States (Tacoma)

1-301-715-8592, United States (Washington DC)

1-312-626-6799, United States (Chicago)

1-346-248-7799, United States (Houston)

1-669-900-6833, United States (San Jose)

Meeting ID: 874 2715 8805

Pass code: 381727

About Hemostemix Inc.

Hemostemix is a publicly traded autologous stem cell therapy company. A winner of the World Economic Forum Technology Pioneer Award, the company developed and is commercializing its lead product ACP-01 for the treatment of CLI (critical limb ischemia), PAD (peripheral artery disease), angina, ischemic cardiomyopathy, dilated cardiomyopathy and other conditions of ischemia. ACP-01 has been used to treat over 500 patients and it is the subject of a randomized, placebo-controlled, double-blind trial of its safety and efficacy in patients with advanced critical limb ischemia who have exhausted all other options to save their limb from amputation.

On Oct. 21, 2019, the company announced the results from its phase II CLI trial abstract entitled "Autologous Stem Cell Treatment for CLI Patients with No Revascularization Options: An Update of the Hemostemix ACP-01 Trial With 4.5 Year Followup," which noted healing of ulcers and resolution of ischemic rest pain occurred in 83 per cent of patients, with outcomes maintained for up to 4.5 years. The company owns 91 patents across five patent families.

We seek Safe Harbor.

© 2021 Canjex Publishing Ltd. All rights reserved.